Sequential Immunotherapy for Alopecia Areata: Phase-Driven Immune Rebalancing
November 2025
in “
Expert Review of Clinical Immunology
”
Research cited in this study
54 / 54 results
research Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
research Pathogenesis and Regenerative Therapy in Vitiligo and Alopecia Areata: Focus on Hair Follicle
Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.
research Healthy Individuals Genetically At-Risk for the Development of Pemphigus Vulgaris or Alopecia Areata Share Disease-Like Cytokine Dysregulation
Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.
research Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Innovative Strategies for the Discovery of New Drugs Against Alopecia Areata: Taking Aim at the Immune System
research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis
Baricitinib is the most effective treatment for alopecia areata.
research Regulatory T Cells in Skin Mediate Immune Privilege of the Hair Follicle Stem Cell Niche
Regulatory T cells protect hair follicle stem cells by maintaining immune privilege in the skin.
research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Alopecia Areata: Current Treatments and New Directions
JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
research Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research Functional Interrogation of Lymphocyte Subsets in Alopecia Areata Using Single-Cell RNA Sequencing
CD8+ T cells drive alopecia areata, while regulatory T cells are protective.
research The Potential of Regulatory T Cell-Based Therapies for Alopecia Areata
Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.
research Baricitinib as the First Systemic Treatment for Severe Alopecia Areata
Baricitinib is effective as a treatment for severe hair loss.
research Alopecia Areata in Latin America: Where Are We and Where Are We Going?
Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
research Scalp Biomarkers During Dupilumab Treatment Support Th2 Pathway Pathogenicity in Alopecia Areata
Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Resident Memory T Cells in Autoimmune Skin Diseases
Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.
research Corticosterone Inhibits GAS6 to Govern Hair Follicle Stem-Cell Quiescence
Stress hormone corticosterone blocks a growth factor to slow down hair stem cell activity and hair growth.
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing Its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata
Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
research Efficacy of Different Concentrations of Intralesional Triamcinolone Acetonide for Alopecia Areata: A Systematic Review and Meta-Analysis
5 mg/mL of triamcinolone acetonide is most effective for hair regrowth with fewer side effects.
research IL-12/IL-23 Neutralization Is Ineffective for Alopecia Areata in Mice and Humans
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
research Frontiers in Alopecia Areata Pathobiology Research
The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
research The Effectiveness of Oral Mini-Pulse Methylprednisolone in the Treatment of Alopecia Areata in Vietnam
Oral mini-pulse methylprednisolone is an effective and safe treatment for alopecia areata.
research JAK Inhibitors and Alopecia Areata
JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
research Alopecia Areata: A Multifactorial Autoimmune Condition
Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
research Alopecia Areata: A Review of Disease Pathogenesis
Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
research Alopecia Universalis Under Adalimumab Therapy in a Patient with Rheumatoid Arthritis
A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.
research Effective Use of Ustekinumab in a Patient with Concomitant Psoriasis, Vitiligo, and Alopecia Areata
Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Adalimumab-Related Alopecia in a Patient Affected by Psoriasis
Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
research Vasoactive Intestinal Peptide, Whose Receptor-Mediated Signaling May Be Defective in Alopecia Areata, Provides Protection from Hair Follicle Immune Privilege Collapse
A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.
research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research Hair Follicle-Derived IL-7 and IL-15 Mediate Skin-Resident Memory T Cell Homeostasis and Lymphoma
Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.
research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
research The Role of Lymphocytes in the Development and Treatment of Alopecia Areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing
Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
research Plasmacytoid Dendritic Cells in Alopecia Areata: Missing Link?
Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.
research The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo
Apremilast may help treat hair loss in alopecia areata.
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?
Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
research Calcitonin Gene-Related Peptide (CGRP) May Award Relative Protection from Interferon-γ-Induced Collapse of Human Hair Follicle Immune Privilege
CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.
research Etiopathogenesis of Alopecia Areata: Why Do Our Patients Get It?
Alopecia areata is a skin condition causing hair loss, and its exact cause is unknown, but it may involve biological mechanisms.
research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack
Hair follicles prevent NK cell attacks to avoid hair loss.
Similar Research
5 / 1000+ resultsresearch Changes in immune status parameters in patients with alopecia areata undergoing combined therapy
Combined therapy reduces inflammation and restores immune balance in alopecia areata patients.
research Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system
research Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine
research Attending persistent T cell activation in alopecia areata : A therapeutic option
Blocking certain proteins on immune cells may help treat alopecia areata.
research Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis
Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.